Ventura Alessandra, Vassall Aaron, Yurter Alp, Robinson Eve, Filler Renata, Hanlon Douglas, Meeth Katrina, Ezaldein Harib, Girardi Michael, Sobolev Olga, Bosenberg Marcus W, Edelson Richard L
Department of Dermatology, Yale University School of Medicine; Dermatology Department, University of Rome Tor Vergata.
Department of Dermatology, Yale University School of Medicine.
J Vis Exp. 2019 May 17(147). doi: 10.3791/59370.
Extracorporeal photochemotherapy (ECP) is a widely used cancer immunotherapy for cutaneous T cell lymphoma (CTCL), operative in over 350 university centers worldwide. While ECP's clinical efficacy and exemplary safety profile have driven its widespread use, elucidation of the underlying mechanisms has remained a challenge, partly owing to lack of a laboratory ECP model. To overcome this obstacle and create a simple, user-friendly platform for ECP research, we developed a scaled-down version of the clinical ECP leukocyte-processing device, suitable for work with both mouse models, and small human blood samples. This device is termed the Transimmunization (TI) chamber, or plate. In a series of landmark experiments, the miniaturized device was used to produce a cellular vaccine that regularly initiated therapeutic anti-cancer immunity in several syngeneic mouse tumor models. By removing individual factors from the experimental system and ascertaining their contribution to the in vivo anti-tumor response, we then elucidated key mechanistic drivers of ECP immunizing potential. Collectively, our results revealed that anti-tumor effects of ECP are initiated by dendritic cells (DC), physiologically generated through blood monocyte interaction with platelets in the TI plate, and loaded with antigens from tumor cells whose apoptotic cell death is finely titrated by exposure to the photoactivatable DNA cross-linking agent 8-methoxypsoralen and UVA light (8-MOPA). When returned to the mouse, this cellular vaccine leads to specific and transferable anti-tumor T cell immunity. We verified that the TI chamber is also suitable for human blood processing, producing human DCs fully comparable in activation state and profile to those derived from the clinical ECP chamber. The protocols presented here are intended for ECP studies in mouse and man, controlled generation of apoptotic tumor cells with 8-MOPA, and rapid production of physiologic human and mouse monocyte-derived DCs for a variety of applications.
体外光化学疗法(ECP)是一种广泛应用于皮肤T细胞淋巴瘤(CTCL)的癌症免疫疗法,在全球350多个大学中心开展。虽然ECP的临床疗效和出色的安全性推动了其广泛应用,但阐明其潜在机制仍然是一项挑战,部分原因是缺乏实验室ECP模型。为了克服这一障碍并创建一个简单、用户友好的ECP研究平台,我们开发了一种临床ECP白细胞处理设备的缩小版,适用于小鼠模型和少量人类血液样本。该设备被称为转免疫(TI)室或板。在一系列具有里程碑意义的实验中,这种小型化设备被用于制备一种细胞疫苗,该疫苗在几种同基因小鼠肿瘤模型中定期引发治疗性抗癌免疫。通过从实验系统中去除各个因素并确定它们对体内抗肿瘤反应的贡献,我们随后阐明了ECP免疫潜力的关键机制驱动因素。总体而言,我们的结果表明,ECP的抗肿瘤作用由树突状细胞(DC)启动,这些树突状细胞通过血液单核细胞与TI板中的血小板相互作用在生理上产生,并负载来自肿瘤细胞的抗原,其凋亡细胞死亡通过暴露于光活化DNA交联剂8-甲氧基补骨脂素和紫外线A光(8-MOPA)进行精确调节。当将这种细胞疫苗回输到小鼠体内时,会产生特异性且可转移的抗肿瘤T细胞免疫。我们验证了TI室也适用于人类血液处理,所产生的人类DC在激活状态和特征方面与临床ECP室产生的DC完全可比。本文介绍的方案适用于小鼠和人类的ECP研究、用8-MOPA可控生成凋亡肿瘤细胞,以及快速制备用于各种应用的生理性人类和小鼠单核细胞来源的DC。